With the third week of July coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions, and miscellany that happened during July 13-17, including 30 pieces.
20. Roche announced on July 13 that the Phase III IMagyn050 study showed that the addition of Tecentriq to Avastin, paclitaxel and carboplatin did not meet its primary endpoint for the front-line treatment of patients with advanced ovarian cancer and did not significantly improve patients’ progression-free survival (PFS) compared to the control group. The safety data of the study were consistent with the known safety profile.
21. NextCure announced the latest progress of the phase 1/2 trial of NC318, its anti-Siglec-15 monoclonal antibody, on July 13. The study planned to enroll up to 100 patients with non-small cell lung cancer (NSCLC), ovarian cancer, head and neck cancer, and triple-negative breast cancer, with the primary endpoints being safety and tolerability. Based on the current enrollment criteria and clinical response data, NextCure will stop the further study of NC318 treating NSCLC and ovarian cancer.
22. Eisai/Biogen announced on July 14 that a new Phase III clinical study (code: AHEAD 3-45) of BAN2401 was formally initiated in the U.S. to evaluate the efficacy of BAN2401 in patients with early asymptomatic Alzheimer’s disease (AD) who have elevated levels of amyloid in the brain. BAN2401 is an anti-Aβ protofibril antibody that selectively binds to neutralize and eliminate soluble toxic Aβ aggregate that participates in the neurodegeneration process of AD.